Aldeyra Therapeutics Inc Research & Development Day Transcript
Welcome to the 2022 Aldeyra Therapeutics Research and Development Day. I am so happy to see many of you here in person. It's great to be back in person again. And thanks to all of you who are listening online as well. We appreciate all the support we get from our investors and have gotten from our investors and analysts and banking friends over the years, it means a lot to us.
By way of introduction, I'm Todd Brady, I am the Chief Executive Officer of Aldeyra. I thought I would begin with an introduction that I don't think any of you have ever heard. In the late '90s, I was a graduate student in the MD, PhD program at Duke University. And I joined a laboratory that was interested in developing drugs to prohibit or inhibit chemical reactions. And the way they were doing that was they were developing drugs they bound to a precursor of those reactions, which is a whole new way of thinking about pharmacology. And I'll talk more about that later on. The problem was that those precursors were too reactive. So to bind those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
